Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Enter your email address below and subscribe to our newsletter

(Image Credit: AdobeStock/natali_mis) Editor’s Note: This content was generated with the assistance of AI. While much of AAO 2025 centered on therapeutics and imaging, AnnMarie Hipsley, PhD, delivered one of the meeting’s most paradigm-shifting talks by re-framing presbyopia as a…

(Image Credit: AdobeStock/Pixel-Shot) Editor’s Note: This content was generated with the assistance of AI. AAO 2025 delivered major insights into anterior segment innovation, spanning corneal cross-linking care, refractive surgery evolution, and energy-based aesthetic technology. Presentations from Reena Gupta, MD; Arjan…

The Viewpoints series “Reimagining Dry Eye Management: Targeting Tear Function for Sustained Relief” convenes leading experts in ophthalmology and optometry to discuss evolving perspectives on dry eye disease (DED). Under the moderation of Kendall Donaldson, MD, MS, the panel—comprising Cecelia…

The Viewpoints series “Reimagining Dry Eye Management: Targeting Tear Function for Sustained Relief” convenes leading experts in ophthalmology and optometry to discuss evolving perspectives on dry eye disease (DED). Under the moderation of Kendall Donaldson, MD, MS, the panel—comprising Cecelia…

(Image Credit: AdobeStock/andrew_shots) Editor’s Note: This content was generated with the assistance of AI. AAO 2025 showcased a powerful convergence of innovation in glaucoma care, emphasizing safer long-term pressure control, improved visualization technologies, and more individualized lens decision-making for complex…

(Image Credit: AdobeStock/Who is Danny) AAVantgarde and AGC Biologics have entered into an agreement in which AGC Biologics will provide Good Manufacturing Practice manufacturing for AAVantgarde’s dual-vector gene therapies for inherited retinal disorders, AAVB-039 and AAVB-081.1 Most recently, AAVantgarde Bio…

(Image Credit: AdobeStock/Julien Tromeur) Editor’s Note: This content was generated with the assistance of AI. At AAO 2025, the conversation around retinal disease treatment moved decisively toward the future—one defined by senolytic agents, next-generation gene and optogenetic therapies, disease-modifying approaches…

(Image Credit: AdobeStock/ronstik) Ocular Therapeutix has randomized the first patient in its HELIOS-3 phase 3 registrational program for AXPAXLI (or OTX-TKI) for the treatment of non-proliferative diabetic retinopathy (NPDR). The company describes AXPAXLI as an investigational, bioresorbable, intravitreal hydrogel incorporating…

(Image Credit: AdobeStock/Mohwet) Editor’s Note: This content was generated with the assistance of AI. AAO 2025 showcased some of the most significant leaps in retinal imaging and disease surveillance the field has seen in over a decade. Three presentations—delivered by…

(Image Credit: AdobeStock/bankoo) Orasis Pharmaceuticals announced the availability of Starter Packs of Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4% to “broaden access for patients seeking a flexible option to manage their presbyopia and allow greater first-hand experience for eye care professionals.”1…